Shin W, Lim KS, Kim MK, Kim HS, Hong J, Jhee S, . . . Cho DY. (2019). A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers. Dove Medical Press.
Chicago Style (17th ed.) CitationShin W, et al. A First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KM-819 (FAS-associated Factor 1 Inhibitor), a Drug for Parkinson’s Disease, in Healthy Volunteers. Dove Medical Press, 2019.
MLA (9th ed.) CitationShin W, et al. A First-in-human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KM-819 (FAS-associated Factor 1 Inhibitor), a Drug for Parkinson’s Disease, in Healthy Volunteers. Dove Medical Press, 2019.